After weeks of anticipation, Gilead Sciences (GILD) finally disclosed the pricing for its remdesivir experimental Covid-19 treatment. But while the number is less than what both investors and a cost-effectiveness watchdog had been expecting, the drug holds the potential to generate plenty of sales. But whether it can generate huge profits is open to debate.

The drug maker will be charging $390 for a vial, which works out to $2,340 per patient for a five-day treatment course, although insurers in the U.S. will pay 33% more, or $3,120. More than 120 low and lower-middle-income countries will get the drug at greatly reduced prices, thanks to licensing and production deals that Gilead struck with several generic manufacturers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Excellent article Ed especially being able to include all the comments from top tier Gilead covering analysts.

    One big unknown I feel is the receptivity of the American people fir the eventual vaccine, regardless of how effective it is from the clinical trial results. What is the % of eligible Americans actually getting vaccinated for influenza during the flu season?
    It’a a a totally different scenario but I typically don’t bother getting flu shots unless I have some confidence in its efficacy despite my PCP’s strong suggestion to get one. I much prefer him to prescribe Tamiflu of zi am exposed to someone I suspect to be suck from flu, then perhaps cough suppressant and azithromycin if I end up with clear URI symptoms. So most likely I would hesitate for any Covid-19 vaccine and try to get remdesivir to slow down Covid-19 then try to get dexamethsdone for cytokine storm.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy